Last reviewed · How we verify
gemcitabine, folinic acid, 5-FU
gemcitabine, folinic acid, 5-FU is a Small molecule drug developed by CONKO-Studiengruppe. It is currently in Phase 2 development. Also known as: gemzar, oncofolic, 5-fu.
At a glance
| Generic name | gemcitabine, folinic acid, 5-FU |
|---|---|
| Also known as | gemzar, oncofolic, 5-fu |
| Sponsor | CONKO-Studiengruppe |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations (PHASE3)
- Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread (PHASE2)
- Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2)
- A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer (PHASE1)
- A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. (PHASE1)
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors (PHASE1)
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gemcitabine, folinic acid, 5-FU CI brief — competitive landscape report
- gemcitabine, folinic acid, 5-FU updates RSS · CI watch RSS
- CONKO-Studiengruppe portfolio CI
Frequently asked questions about gemcitabine, folinic acid, 5-FU
What is gemcitabine, folinic acid, 5-FU?
gemcitabine, folinic acid, 5-FU is a Small molecule drug developed by CONKO-Studiengruppe.
Who makes gemcitabine, folinic acid, 5-FU?
gemcitabine, folinic acid, 5-FU is developed by CONKO-Studiengruppe (see full CONKO-Studiengruppe pipeline at /company/conko-studiengruppe).
Is gemcitabine, folinic acid, 5-FU also known as anything else?
gemcitabine, folinic acid, 5-FU is also known as gemzar, oncofolic, 5-fu.
What development phase is gemcitabine, folinic acid, 5-FU in?
gemcitabine, folinic acid, 5-FU is in Phase 2.
Related
- Manufacturer: CONKO-Studiengruppe — full pipeline
- Also known as: gemzar, oncofolic, 5-fu
- Compare: gemcitabine, folinic acid, 5-FU vs similar drugs
- Pricing: gemcitabine, folinic acid, 5-FU cost, discount & access